First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.

Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medication. This study is conducted in 7 countries in and outside Europe including Poland. First participants were included in the study at the clinical site in Katowice (Poland). The study, managed by Hendrik Wessels , Polpharma Biologics Clinical Development team, led by Karsten Roth , Director Clinical Research & Development, is an essential part of the development program for the proposed Biosimilar to Natalizumab. More information can be found here

The release as fetched from its publisher. polpharmabiologics.com ↗